GE Healthcare Technologies (GEHC) said Monday it completed the acquisition of the remaining 50% stake it doesn't own in Japanese radiopharmaceutical company Nihon Medi-Physics from Sumitomo Chemical.
As part of the deal, Kevin O'Neill, the chief executive of GE Healthcare's pharmaceutical diagnostics segment, will become president of Nihon Medi-Physics.
The company expects the transaction, which was disclosed in December, to be neutral to adjusted earnings per share in year one and accretive afterwards.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.